ST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) --

圣路易斯和法国鲁昂，2026年7月9日（环球新闻社）--

Stereotaxis

立体定向

(NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previously announced acquisition of Robocath, an innovator of robotic technologies for interventional cardiology and neurointerventions.

（纽约证券交易所代码：STXS）作为微创血管内介入手术机器人领域的先驱和全球领导者，今日宣布已完成此前公布的对Robocath的收购。Robocath是介入心脏病学和神经介入机器人技术的创新者。

Robocath will now be fully integrated into Stereotaxis, combining complementary technologies and expertise to accelerate the development of next-generation robotic solutions for electrophysiology, interventional cardiology, and neurointerventions. The combined platform strengthens Stereotaxis’s position as the leader in robotic technologies across the full spectrum of endovascular procedures..

Robocath 现已完全并入 Stereotaxis，双方将融合互补的技术与专业知识，加速开发用于电生理学、介入心脏病学和神经介入的下一代机器人解决方案。这一合并平台进一步巩固了 Stereotaxis 作为涵盖全部血管内手术领域的机器人技术领导者的地位。

“We’re very excited to join Stereotaxis,” said Philippe Bencteux, Robocath Founder and CEO. “Combining the strengths, expertise, and technologies of two pioneers in endovascular robotics, we now have the opportunity to accelerate innovation, expand our global reach, and bring robotic solutions to many more physicians and patients around the world.”.

“我们非常高兴加入 Stereotaxis，”Robocath 创始人兼首席执行官 Philippe Bencteux 表示。“通过结合两家血管内机器人先驱企业的优势、专业知识和技术，我们现在有机会加速创新，扩大全球影响力，并为全球更多的医生和患者提供机器人解决方案。”

“The addition of Robocath’s technology and team to Stereotaxis accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies in an expanded addressable market, and supports new strategic opportunities,” said David Fischel, Stereotaxis Chairman and CEO.

“将Robocath的技术和团队纳入Stereotaxis，加速了我们的战略实施，增强了我们的技术领先地位，在扩大的可及市场中提供了具有吸引力的商业协同效应，并支持新的战略机遇。” Stereotaxis董事长兼首席执行官David Fischel表示。

About Stereotaxis

关于 Stereotaxis

Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room.

Stereotaxis（纽约证券交易所代码：STXS）是微创血管内介入手术创新机器人领域的先驱和全球领导者。其使命是为介入实验室发现、开发和提供机器人系统、器械及信息化解决方案。这些创新帮助医生以机器人的精准度和安全性提供无与伦比的患者护理，扩大微创治疗的可及性，并提升手术室的生产力、连通性和智能化水平。

Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit .

立体定向技术已在美国、欧洲、亚洲及其他地区用于治疗超过15万名患者。欲了解更多信息，请访问。

www.stereotaxis.com

www.stereotaxis.com

.

。

About Robocath

关于 Robocath

Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and markets smart robotic solutions to treat cardiovascular and neurovascular diseases. Robocath robotic solutions integrate a unique bionic technology that optimizes the safety of robotic-assisted coronary angioplasty. Robocath’s robotic solutions are designed to operate with precision and perform accurate movements, creating better interventional conditions.

Robocath 由 Philippe Bencteux 医学博士于 2009 年创立，致力于设计、开发和营销用于治疗心血管及神经血管疾病的智能机器人解决方案。Robocath 的机器人解决方案融合了独特的仿生技术，可优化机器人辅助冠状动脉成形术的安全性。其机器人解决方案旨在实现精准操作和精确运动，从而创造更优的介入治疗条件。

Robocath has obtained CE and NMPA certifications for its first robotic solution. Several multicenter clinical studies have been conducted, and a meta-analysis has demonstrated R-One’s safety and efficacy as it achieved more than 98% technical procedure success with no major adverse cardiovascular events.

Robocath 的首款机器人解决方案已获得 CE 认证和中国国家药品监督管理局（NMPA）认证。已开展多项多中心临床研究，一项荟萃分析证实了 R-One 的安全性和有效性，其技术操作成功率超过 98%，且无重大不良心血管事件发生。

Currently R-One is used in Europe and China. Robocath, based in Rouen (France), a world leader in vascular robotics, continues to push the boundaries of interventional cardiology technology by developing smart digital solutions. Its ambition is to guarantee equal access to treatment for vascular emergencies through the development of remote interventions, offering the best care for all..

目前，R-One已在欧洲和中国投入使用。Robocath总部位于法国鲁昂，是全球血管机器人领域的领导者，通过开发智能数字解决方案，不断突破介入心脏病学技术的边界。其雄心是通过发展远程介入手术，确保血管急症患者享有平等的治疗机会，为所有患者提供最优护理。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示说明

This press release includes statements that may constitute 'forward-looking' statements, usually containing the words 'believe”, 'estimate”, 'project”, 'expect' or similar expressions. These forward-looking statements include without limitation statements regarding the recently completed acquisition of Robocath, the anticipated financial performance of Stereotaxis and Robocath related thereto, including the anticipated benefits expected from the acquisition, the potential strategic implications as a result of the acquisition, and the potential for achievement of the regulatory and commercial milestones that would trigger contingent payments in the transaction.

本新闻稿包含可能构成“前瞻性”陈述的语句，通常含有“相信”、“估计”、“预测”、“预期”或类似表述。这些前瞻性陈述包括但不限于关于最近完成的对Robocath收购的陈述、Stereotaxis和Robocath与此相关的预期财务表现（包括此次收购预期带来的收益）、此次收购可能产生的战略影响，以及实现可能触发交易中或有支付义务的监管和商业里程碑的潜力。

Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involving the following: the ability of Stereotaxis to successfully integrate Robocath’s operations, and continue the commercialization, development and sales of Robocath’s products and services, and disruption of Robocath’s or Stereotaxis’s current plans and operations as a result thereof; the ability of Robocath or Stereotaxis to retain and hire key personnel; competitive responses to the proposed transaction; unexpected costs, charges or expenses resulting from the proposed transaction; the ability of Stereotaxis to implement its plans, forecasts and other expectations with respect to Robocath’s business following the completion of the transaction and realize additional opportunities for growth and innovation; the ability of Stereotaxis to realize the anticipated benefits from the transaction in the anticipated amounts or within the anticipated timeframes or at all; the ability to main.

前瞻性陈述 inherently 涉及风险和不确定性，可能导致实际结果出现重大差异。导致或促成此类差异的因素包括但不限于以下方面的不确定性：Stereotaxis 成功整合 Robocath 运营、并持续推进 Robocath 产品和服务的商业化、开发及销售的能力，以及由此对 Robocath 或 Stereotaxis 当前计划和运营造成的干扰；Robocath 或 Stereotaxis 留住和聘用关键人员的能力；对拟议交易的竞争性反应；因拟议交易而产生的意外成本、费用或支出；Stereotaxis 在交易完成后实施其针对 Robocath 业务的计划、预测及其他预期，并实现额外增长和创新机会的能力；Stereotaxis 能否按预期金额或在预期时间框架内（或根本）实现交易带来的预期收益；维持能力。

By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Additional information will also be set forth in future filings that we make with the SEC from time to time. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

通过发表这些前瞻性陈述，本公司不承担在本新闻稿发布日后对这些陈述进行修订或变更更新的义务。我们还将不时向美国证券交易委员会（SEC）提交的文件中提供更多信息。本新闻稿中的所有前瞻性陈述均基于截至本文日期我们可获得的信息，我们不承担任何义务去更新所提供的前瞻性陈述以反映在其作出之后发生的事件或存在的情况。

There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled..

无法保证公司将确认与其采购订单及其他承诺相关的收入，因为其中部分采购订单及其他承诺受制于公司控制范围之外的偶然事件，并可能被修订、修改、延迟或取消。

Company Contacts:

公司联系人：

David L. Fischel

大卫·L·菲谢尔

Chairman and Chief Executive Officer

董事长兼首席执行官

Kimberly R. Peery

金伯利·R·皮里

Chief Financial Officer

首席财务官

314-678-6100

314-678-6100

Investors@Stereotaxis.com

投资者@Stereotaxis.com